Onyx Biotec Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Onyx Biotec Ltd is ₹ 34.7 as of 05 May 15:30 . The P/E Ratio of Onyx Biotec Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Onyx Biotec Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Onyx Biotec Ltd changed from 0 % on March 2022 to 0 % on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2022 to 0 % on March 2025 . This represents a CAGR of 0.0% over 4 years .

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Onyx Biotec Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Onyx Biotec Ltd or Sai Parenterals Ltd?

Market cap of Onyx Biotec Ltd is 63 Cr while Market cap of Sai Parenterals Ltd is 2,118 Cr

What are the key factors driving the stock performance of Onyx Biotec Ltd and Sai Parenterals Ltd?

The stock performance of Onyx Biotec Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Onyx Biotec Ltd and Sai Parenterals Ltd?

As of May 5, 2026, the Onyx Biotec Ltd stock price is INR ₹35.05. On the other hand, Sai Parenterals Ltd stock price is INR ₹479.5.

How do dividend payouts of Onyx Biotec Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Onyx Biotec Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.